Pharmorage is the result of a strategic collaboration between the ASX listed Noxopharm Limited and Melbourne’s Hudson Institute of Medical Research, created to enhance mRNA vaccine technology and to discover and develop new treatments for a wide range of autoimmune and inflammatory diseases.